BioToxTech Co

BioToxTech Co Inventory Turnover

The Inventory Turnover Ratio of BioToxTech Co (086040.KQ) as of Oct 20, 2026 is 5.70. In the previous year, Inventory Turnover Ratio was 2.62 — a change of 117.28% (higher).

Inventory Turnover

5.70

YoY

117.28%

Last updated:

Inventory Turnover Ratio of BioToxTech Co is 2025 5.70 . Inventory Turnover Ratio of BioToxTech Co was 2024 2.62 . It decreases by 117.28% higher compared to the previous year.

The BioToxTech Co Inventory Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory Turnover
Date
Inventory Turnover
Jan 1, 2018
20.21 KRW
Jan 1, 2019
28.92 KRW
Jan 1, 2020
21.97 KRW
Jan 1, 2021
30.41 KRW
Jan 1, 2022
5.13 KRW
Jan 1, 2023
2.27 KRW
Jan 1, 2024
2.62 KRW
Jan 1, 2025
5.70 KRW
The BioToxTech Co Inventory Turnover history
YEARInventory TurnoverYoY
5.70+117.28%
2.62+15.53%
2.27-55.78%
5.13-83.12%
30.41+38.41%
21.97-24.02%
28.92+43.09%
20.21+16.07%
17.41+0.45%
17.34-15.52%
20.52+5.22%
19.50—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Inventory Turnover Ratio of BioToxTech Co is 5.70 in 2025.

Inventory Turnover Ratio of BioToxTech Co changed from 2.62 to 5.70, representing a 117.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Turnover Ratio BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Inventory turnover measures how many times inventory is sold and replaced during a period. Higher turnover indicates efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Inventory Turnover Ratio's BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Inventory Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Inventory Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BioToxTech Co

All Key Metrics — BioToxTech Co